Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Journal: Hematological oncology
Published: January 23, 2026
Tumor Board-Inspired Multiagent Artificial Intelligence System for Interpreting Oncology Guidelines.
Tumor Board-Inspired Multiagent Artificial Intelligence System for Interpreting Oncology Guidelines.
Journal: JCO clinical cancer informatics
Published: January 07, 2026
Autonomous Analysis of Curated Patient Data Using a Large Language Model-Based Multiagent Framework.
Autonomous Analysis of Curated Patient Data Using a Large Language Model-Based Multiagent Framework.
Journal: JCO clinical cancer informatics
Published: December 19, 2025
Clinical utility of interim bone marrow biopsies in FLT3 mutant acute myeloid leukemia.
Journal: Leukemia research
Published: September 10, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.
Journal: American journal of hematology
Published: March 21, 2025
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax.
Journal: Leukemia & lymphoma
Published: February 04, 2025
U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAs.
Journal: Molecular cell
Published: October 25, 2024
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations.
Journal: Seminars in hematology
Published: July 21, 2024
A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with NPM1 and IDH2 mutations.
Journal: Leukemia research reports
Published: February 22, 2024
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
Journal: Leukemia research
Published: March 30, 2023
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Journal: American journal of hematology
Published: January 20, 2022
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Journal: Blood cancer discovery
Published: September 29, 2021
Last Updated: 09/26/2026